Redhawk Wealth Advisors Inc. Purchases 455 Shares of Cencora, Inc. (NYSE:COR)

Redhawk Wealth Advisors Inc. grew its position in shares of Cencora, Inc. (NYSE:COR) by 4.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,747 shares of the company’s stock after purchasing an additional 455 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Cencora were worth $3,267,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC increased its stake in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Cencora in the 4th quarter valued at $29,000. SBI Securities Co. Ltd. bought a new stake in shares of Cencora in the 4th quarter valued at $30,000. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter valued at $33,000. Finally, WASHINGTON TRUST Co increased its stake in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

COR opened at $284.32 on Wednesday. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $55.11 billion, a price-to-earnings ratio of 40.44, a P/E/G ratio of 1.31 and a beta of 0.58. The firm’s fifty day moving average price is $286.28 and its two-hundred day moving average price is $260.81. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.80 EPS. As a group, analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend was Friday, May 16th. Cencora’s dividend payout ratio is 25.52%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on COR. Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. Wells Fargo & Company raised shares of Cencora from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Finally, Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $306.91.

Insiders Place Their Bets

In related news, EVP Elizabeth S. Campbell sold 4,127 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at approximately $3,934,326.20. The trade was a 21.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the business’s stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. This trade represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,253 shares of company stock valued at $10,582,297 in the last three months. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.